BJDX

Insider Trades

Name	Value	Action	Price	Current Price
Chase Donald RDirector $25k12.5k shares BuyMar 14, 2026 $2.00 --
Dey IndranilDirector, Officer: President And CEO $25k12.5k shares BuyMar 14, 2026 $2.00 --
Dey SvetlanaDirector $25k12.5k shares BuyMar 14, 2026 $2.00 --
Wurth Douglas ClarkDirector $25k12.5k shares BuyMar 14, 2026 $2.00 --
Zeidman Fred SDirector $25k12.5k shares BuyMar 14, 2026 $2.00 --

News

globenewswire.comBluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rulesglobenewswire.comJun 5

benzinga.comWhat's Going On With Bluejay Diagnostics Shares On Wednesday?benzinga.comJun 3

globenewswire.comBluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.comJun 2

globenewswire.comBluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnershipglobenewswire.comJun 2

globenewswire.comBluejay Diagnostics Provides First Quarter 2026 Corporate Updateglobenewswire.comMay 7

Trade BJDX

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.

CEO: Indranil Dey
IPO Date: Nov 10, 2021

Market Data

Open: $4.48
High: $4.72
Low: $4.35
Volume: 79.4K
Avg Volume: 1.3M
52W High: $16.68
52W Low: $1.62

Valuation

Market Cap: $2.0M
Enterprise Value: $-1.6M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-6.2M
Revenue: $0
Net Income: $-6.8M
Cash: $5.2M
Debt: $130k

Events

EarningsAug 19

EPS est. -3520